Tirzepatide Tablet Research: Oral Versions in Trials

Last updated: May 2026 · Medically reviewed by Dr. Laura Bennett, MD, MPH

Medical Disclaimer: This article is for informational purposes only and is not medical advice. Tirzepatide is a prescription medication. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Tirzepatide has reshaped obesity and diabetes care since FDA approval. It is the active ingredient in Mounjaro (approved 2022 for type 2 diabetes) (FDA, 2022) and Zepbound (approved 2023 for chronic weight management) (FDA, 2023).

Both are once-weekly subcutaneous injections. Patients regularly ask: when will a tirzepatide tablet exist?

Short answer: there is no oral tirzepatide tablet in development that has been publicly disclosed by Eli Lilly. Lilly's oral strategy is built around a different molecule entirely — orforglipron, a small-molecule non-peptide GLP-1 agonist that does not require the absorption-enhancer machinery of an oral peptide.

This guide explains what tirzepatide does, the SURMOUNT and SURPASS evidence, and where oral options stand in 2026.

What is Tirzepatide and How Does it Work?

Tirzepatide is a 39-amino-acid synthetic peptide that activates two receptors at once: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). That dual mechanism distinguishes it from semaglutide.

The pharmacology is detailed in the Zepbound prescribing information (FDA 2023).

The Dual Action of GIP and GLP-1

GIP and GLP-1 are incretin hormones — gut peptides released in response to food. They prompt insulin release, suppress glucagon, slow gastric emptying, and act on satiety centers in the brain.

Single-agonist drugs (semaglutide, liraglutide) hit GLP-1 only. Tirzepatide hits both, which is why head-to-head data in SURPASS-2 published in NEJM showed tirzepatide outperformed semaglutide on A1C and body weight in patients with type 2 diabetes (NEJM, 2021).

Regulating Blood Sugar

Tirzepatide stimulates insulin release only when blood glucose is elevated. That glucose-dependent mechanism limits hypoglycemia risk in monotherapy.

It also reduces glucagon output from the liver. The combined effect lowers fasting and post-meal glucose per the ADA Standards of Care in Diabetes-2024 (ADA, 2024).

Impact on Digestion and Satiety

Tirzepatide slows gastric emptying. Food stays in the stomach longer, which blunts post-meal glucose spikes and extends fullness.

The slowed emptying is also why nausea is the most common side effect. Most patients report symptoms ease after the first few weeks at each new dose step per Zepbound label safety data (FDA 2023).

Appetite Reduction and Insulin Sensitivity

Beyond gut effects, tirzepatide reaches the central nervous system. It modulates appetite circuits in the hypothalamus and reward pathways that drive food-seeking.

The drug also improves insulin sensitivity. Cells become more responsive to circulating insulin, which is a core mechanism for type 2 diabetes management.

What are the Approved Uses for Tirzepatide?

Tirzepatide is sold under two brand names with separate indications. The molecule is identical; the labels differ.

Mounjaro: Type 2 Diabetes

Mounjaro received FDA approval in May 2022 for blood-glucose control in adults with type 2 diabetes. It is dosed as a once-weekly subcutaneous injection.

The pivotal SURPASS program showed Mounjaro reducing A1C by 1.9-2.4% across doses per pooled data in SURPASS-2 NEJM (NEJM 2021). For comparison with semaglutide on diabetes outcomes, see our tirzepatide vs semaglutide diabetes head-to-head.

Zepbound: Chronic Weight Management and Sleep Apnea

Zepbound was approved in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity per the FDA approval announcement (FDA 2023).

In December 2024, the FDA expanded Zepbound's label to include moderate-to-severe obstructive sleep apnea in adults with obesity. That made it the first prescription drug approved for OSA.

Expanding Indications: Obstructive Sleep Apnea

The OSA approval was based on SURMOUNT-OSA trial data. Patients on tirzepatide saw substantial reductions in the apnea-hypopnea index plus meaningful weight loss.

That second indication is part of why obesity-medicine physicians increasingly view tirzepatide as a multi-organ therapy, not just a weight drug.

What Weight Loss Results Can Be Expected with Tirzepatide?

The SURMOUNT trials defined tirzepatide's weight-loss profile. Results have been replicated across multiple populations.

Significant Average Weight Loss

In SURMOUNT-1 published in NEJM, patients on tirzepatide 15 mg lost an average 20.9% of body weight over 72 weeks (NEJM, 2022). Placebo arm: 3.1%.

That ~17.8 percentage-point advantage is the largest pharmacological weight-loss effect ever recorded in a Phase 3 obesity trial.

High Rates of Clinically Meaningful Weight Loss

Beyond averages, 91% of patients on tirzepatide 15 mg hit ≥5% weight loss in SURMOUNT-1. About 57% reached ≥20%.

Clinically, even 5% loss improves blood pressure, lipids, and glycemic markers per ADA standards (ADA 2024). Hitting 20% changes the trajectory of obesity-related disease entirely.

Long-Term Maintenance of Weight Reduction

SURMOUNT-4, published in JAMA in 2023, tested what happens after the initial loss phase (JAMA, 2023). Patients who continued tirzepatide maintained or extended their weight loss; those switched to placebo regained roughly half their lost weight within a year.

The takeaway: tirzepatide works as a chronic therapy. Stopping it leads to regain, consistent with the underlying chronic-disease model of obesity.

The SURMOUNT-5 head-to-head against semaglutide confirmed tirzepatide's edge: 20.2% vs 13.7% mean weight loss over 72 weeks (NEJM, 2025).

What are the Common Side Effects of Tirzepatide?

Tirzepatide's side-effect profile is dominated by gastrointestinal symptoms. Most are mild-to-moderate and improve over time.

Frequent Gastrointestinal Side Effects

Per the Zepbound label safety table, the most common adverse reactions at the 15 mg dose include:

Side Effect	Incidence
Nausea	29%
Diarrhea	21%
Constipation	11%
Vomiting	13%
Abdominal pain	10%
Injection-site reactions	8%

Source: Zepbound prescribing information, FDA, 2023.

Strategies for Managing Side Effects

Smaller, more frequent meals reduce post-injection nausea. Skipping high-fat and greasy foods during the first 48 hours after a dose helps too.

Hydration matters — diarrhea and vomiting can dehydrate quickly. Some patients use anti-nausea medications like ondansetron during the first dose at each new titration step.

Importance of Gradual Dosing

The titration schedule (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg) exists for tolerability. Each dose is held for at least 4 weeks before stepping up.

Skipping titration steps drives side effects sharply higher. Follow your prescriber's schedule.

Are There Serious Side Effects and Contraindications?

Tirzepatide carries serious warnings that every patient must understand before starting.

Black Box Warning: Thyroid C-Cell Tumors

Tirzepatide carries an FDA boxed warning for risk of thyroid C-cell tumors based on rodent studies. The warning is documented in the Zepbound label (FDA 2023).

It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Whether the rodent finding translates to humans remains unclear.

Other Serious Side Effects

The FDA label also lists warnings for acute pancreatitis, acute gallbladder disease, hypoglycemia (when used with insulin or sulfonylureas), acute kidney injury (from severe GI side effects), diabetic retinopathy complications, and severe hypersensitivity reactions.

Severe abdominal pain radiating to the back warrants immediate evaluation for pancreatitis.

Contraindications and Important Safety Information

Tirzepatide should not be used in type 1 diabetes. It is also contraindicated in patients with prior severe hypersensitivity to the drug or any excipient.

Caution applies to patients with a history of pancreatitis or severe gastrointestinal disease.

What is the Status of Oral Tirzepatide Research?

Currently, tirzepatide exists only as a once-weekly injection. The question of an oral tablet is more complicated than most patients realize.

The Search for Oral GLP-1/GIP Agonists

Tirzepatide is a 39-amino-acid peptide. Peptides this size are hard to deliver orally because they get broken down by stomach acid and digestive enzymes before they can be absorbed.

Novo Nordisk solved part of this puzzle with Rybelsus (oral semaglutide), which uses an absorption enhancer called SNAC to ferry the peptide across the gastric mucosa (FDA, 2019). Bioavailability is still low (~1%), which is why Rybelsus requires strict fasting protocols.

Lilly's Oral Strategy: Orforglipron, Not Oral Tirzepatide

Eli Lilly's publicly disclosed oral GLP-1 program centers on orforglipron, a small-molecule non-peptide GLP-1 receptor agonist. Because it is not a peptide, orforglipron does not require absorption enhancers and has no food restrictions.

Lilly's ACHIEVE-1 Phase 3 readout in April 2025 showed orforglipron met its primary endpoints in adults with type 2 diabetes. ATTAIN-1 (obesity) topline data are expected to support an FDA filing by end of 2026.

Lilly has not publicly disclosed an oral tirzepatide tablet program. The dual GIP/GLP-1 mechanism is harder to engineer into a small molecule, and the company's resources appear concentrated on orforglipron.

Current Focus of Tirzepatide Trials

Active tirzepatide trials are listed on ClinicalTrials.gov NCT04660643 maintenance trial and similar studies (ClinicalTrials.gov, 2024). Trial focus is on maintenance of weight loss, cardiovascular outcomes (SURMOUNT-MMO), kidney outcomes, MASH/MASLD, and pediatric populations.

If you want oral peptide therapy today, Rybelsus (oral semaglutide) is the only FDA-approved oral GLP-1 (FDA, 2019). It is approved for diabetes but lacks tirzepatide's GIP mechanism.

For the oral pill landscape generally, see our GLP-1 pill vs injection guide.

Frequently Asked Questions

What is the difference between Zepbound and Mounjaro?

Zepbound and Mounjaro contain the same active ingredient, tirzepatide, and work the same way by activating GIP and GLP-1 receptors. The difference is the FDA-approved indication. Mounjaro is approved for blood-glucose control in adults with type 2 diabetes; Zepbound is approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Insurance coverage and pricing differ between the two brands, which is the main practical reason to ask your prescriber which label fits your situation.

How often is tirzepatide administered?

Tirzepatide is administered once weekly as a subcutaneous injection. Patients self-inject into the abdomen, thigh, or upper arm. The same dose-titration schedule applies whether it is branded as Mounjaro or Zepbound, starting at 2.5 mg and stepping up over 20+ weeks to the maintenance dose.

Can tirzepatide be used for type 1 diabetes?

No. Tirzepatide is not approved or recommended for type 1 diabetes. Its insulin-secretagogue mechanism requires functional pancreatic beta cells, which type 1 diabetes patients lack. Both the Mounjaro and Zepbound labels exclude type 1 diabetes as a clinical use case per FDA label (FDA 2023).

What should I do if I experience severe side effects?

Severe abdominal pain (especially if it radiates to the back), persistent vomiting preventing fluid intake, neck swelling, hoarseness, difficulty swallowing, or severe allergic reactions require immediate medical attention. These can signal pancreatitis, thyroid issues, or anaphylaxis. Always contact your prescriber for less severe but persistent symptoms — they can adjust dose or recommend supportive care.

Are there generic versions of Zepbound or Mounjaro available?

No. There are no generic or authorized-generic versions of tirzepatide available in the United States in 2026. Tirzepatide's primary composition-of-matter patents extend into the 2030s, so generics are not expected in this decade. The FDA-regulated compounding pharmacy pathway for tirzepatide ended in 2025 when Lilly officially resolved the FDA shortage list per FDA's compounding guidance (FDA 2024).